Journal of Shanghai Jiao Tong University (Medical Science) >

2021 , Vol. 41 >Issue 4: 525 - 529

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.04.018

Review

Advances in epidemiology and treatment of invasive Candida infection in the immunocompromised population

  • Lin LIU ,
  • Hui WANG ,
  • Ning-ning LIU
Expand
  • School of Public Health, Shanghai Jiao Tong University, Shanghai 200025, China

Received date: 2020-03-17

  Online published: 2021-05-14

Supported by

National Key Research and Development Program of China(2018YFC2000700);National Nature Science Foundation of China(81630086);Key Research Program of Chinese Academy of Sciences(ZDRW-ZS-2017-1);Major Science and Technology Innovation Program of Shanghai Municipal Education Commission(2019-01-07-00-01-E00059);Program for Young Eastern Scholar at Shanghai Institutions of Higher Learning(QD2018016);Shanghai Pujiang Program(18PJ1406600);Medicine and Engineering Interdisciplinary Research Fund of Shanghai Jiao Tong Univesity(YG2020YQ06);Innovative Research Team of High-level Local Universities in Shanghai(SSMU-ZLCX20180302)

Fold

Abstract

With the development of modern medical technology, such as organ transplantation, the extensive application of broad-spectrum antibiotics and immunosuppressants and the prolongation of human life span, the number of people with low immunity is increasing. The morbidity and mortality of invasive fungal infection are increasing in these population. Invasive fungal infection has become the direct cause of death of critical diseases, such as malignant tumor and organ transplantation. Candida is the primary pathogenic fungi of invasive fungal infection. It can infect human subcutaneous tissue, mucous membrane, other tissues and organs of the whole body, and then spread in the blood. The main clinical manifestations of Candida infectionare candidemia and deep candidiasis, and the prognosis is often poor. At present, antifungal infection is still the main treatment for invasive Candida (IC) in immunocompromised population, and drug treatment is one of the effective ways. Clinical conventional antifungal drugs include polyenes, azoles and echinocandins. Among them, echinocandins is the first choice for the treatment of IC. However, the existing treatments fail to improve the prognosis of patients with IC infection, and drug resistance caused by long-term use frequently occurr. At present, the number of antifungal drugs available is extremely limited. Therefore, in order to solve the above problems, drug combination therapy, adjuvant immunotherapy, photodynamic therapy and laser therapy provide new perspectives for the treatment of IC. This article reviews the epidemiology and treatment of IC infetcion in the population with low immunity. In this paper, the incidence and mortality of IC infection in patients in intensive care unit, patients with hematological malignancies, solid organ transplant patients, neonates, the elderly, and human immunodeficiency virus (HIV)-infected people at home and abroad, and the distribution of main pathogenic Candida species, as well as the therapeutic potential and limitations of new research were discussed in depth. The future research direction was proposed.

Key words： immunocompromised population; invasive Candida infection; epidemiology; anti-Candida infection

Cite this article

Lin LIU , Hui WANG , Ning-ning LIU . Advances in epidemiology and treatment of invasive Candida infection in the immunocompromised population[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(4) : 525 -529 . DOI: 10.3969/j.issn.1674-8115.2021.04.018

References

1 扈东营, 姜伟伟, 李航, 等. 侵袭性念珠菌感染流行病学现状和治疗进展[J]. 世界临床药物, 2020, 41(05):323-28.
2 Enoch DA, Yang H, Aliyu SH, et al. The changing epidemiology of invasive fungal infections[J]. Methods Mol Biol, 2017, 1508:17-65.
3 Vincent JL, Sakr Y, Singer M, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017[J]. JAMA, 2020, 323(15):1478-1487.
4 Chakrabarti A, Sood P, Rudramurthy SM, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India[J]. Intensive Care Med, 2015, 41(2):285-295.
5 Bassetti M, Giacobbe DR, Vena A, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project[J]. Crit Care, 2019, 23(1):219.
6 Guo FM, Yang Y, Kang Y, et al. Invasive candidiasis in intensive care units in China: a multicentre prospective observational study[J]. J Antimicrob Chemother, 2013, 68(7): 1660-1668.
7 Cortegiani A, Misseri G, Giarratano A, et al. The global challenge of Candida auris in the intensive care unit[J]. Crit Care, 2019, 23(1):150.
8 Keighley C, Chen SC, Marriott D, et al. Candidaemia and a risk predictive model for overall mortality: a prospective multicentre study[J]. BMC Infect Dis, 2019, 19(1):445.
9 Corzo-León DE, Satlin MJ, Soave R, et al. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens[J]. Mycoses, 2015, 58(6):325-336.
10 Criscuolo M, Marchesi F, Candoni A, et al. Fungaemia in haematological malignancies: SEIFEM-2015 survey[J]. Eur J Clin Invest, 2019, 49(5):e13083.
11 Sun Y, Meng F, Han M, et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study[J]. Biology Blood Marrow Transplantat, 2015, 21(6):1117-1126.
12 Chen CY, Tien FM, Sheng WH, et al. Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008-2013[J]. Int J Antimicrob Agents, 2017, 49(3):272-281.
13 Andes DR, Safdar N, Baddley JW, et al. The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET) [J]. Transpl Infect Dis, 2016, 18(6):921-931.
14 Fernández-Ruiz M, Cardozo C, Salavert M, et al. Candidemia in solid organ transplant recipients in Spain: epidemiological trends and determinants of outcome[J]. Transpl Infect Dis, 2019, 21(6):e13195.
15 Benedict K, Roy M, Kabbani S, et al. Neonatal and pediatric Candidemia: results from population-based active laboratory surveillance in four US locations, 2009-2015[J]. J Pediatric Infect Dis Soc, 2018, 7(3):e78-e85.
16 Warris A, Pana ZD, Oletto A, et al. Etiology and outcome of Candidemia in neonates and children in Europe: an 11-year multinational retrospective study[J]. Pediatric Infect Dis J, 2020, 39(2):114-120.
17 Hsu JF, Lai MY, Lee CW, et al. Comparison of the incidence, clinical features and outcomes of invasive candidiasis in children and neonates[J]. BMC Infect Dis, 2018, 18(1):194.
18 Toda M, Williams SR, Berkow EL, et al. Population-based active surveillance for culture-confirmed Candidemia-four sites, United States, 2012-2016[J]. MMWR Surveill Summ, 2019, 68(8):1-15.
19 Luzzati R, Cavinato S, Deiana ML, et al. Epidemiology and outcome of nosocomial candidemia in elderly patients admitted prevalently in medical wards[J]. Aging Cli Exp Res, 2015, 27(2):131-137.
20 Lerma A, Cantero E, Soriano M, et al. Clinical presentation of candidaemia in elderly patients: experience in a single institution[J]. Rev Esp Quimioter, 2017, 30(3):207-212.
21 Ramos-Martínez A, Vicente-López N, Sánchez-Romero I, et al. Epidemiology and prognosis of candidaemia in elderly patients[J]. Mycoses, 2017, 60(12):808-17.
22 Tang HJ, Liu WL, Lin HL, et al. Epidemiology and prognostic factors of candidemia in elderly patients[J]. Geriatr Gerontol Int, 2015, 15(6):688-693.
23 Taramasso L, Tatarelli P, Di Biagio A. Bloodstream infections in HIV-infected patients[J]. Virulence, 2016, 7(3):320-328.
24 Buchacz K, Lau B, Jing Y, et al. Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000-2010[J]. J Infect Dis, 2016, 214(6):862-872.
25 Pang W, Shang P, Li Q, et al. Prevalence of opportunistic infections and causes of death among hospitalized HIV-infected patients in Sichuan, China[J]. Tohoku J Exp Med, 2018, 244(3):231-242.
26 Katragkou A, McCarthy M, Meletiadis J, et al. In vitro combination therapy with isavuconazole against Candida spp.[J]. Med Mycol, 2017, 55(8):859-868.
27 Bidaud AL, Botterel F, Chowdhary A, et al. In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism[J]. Antimicrob Agents Chemother, 2019, 63(12):e01393-19.
28 Shrestha SK, Fosso MY, Garneau-Tsodikova S. A combination approach to treating fungal infections[J]. Sci Rep, 2015, 5:17070.
29 Li H, Zhang C, Liu P, et al. In vitro interactions between fluconazole and minocycline against mixed cultures of Candida albicans and Staphylococcus aureus[J]. J Microbiol Immunol Infect, 2015, 48(6):655-661.
30 Li L, An M, Shen H, et al. The non-Geldanamycin Hsp90 inhibitors enhanced the antifungal activity of fluconazole[J]. Am J Transl Res, 2015, 7(12):2589-2602.
31 Jia W, Zhang H, Li C, et al. The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms[J]. BMC Microbiol, 2016, 16(1):113.
32 Pfaller MA, Rhomberg PR, Messer SA, et al. In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species[J]. Diagn Microbiol Infect Dis, 2015, 81(4):259-263.
33 Khan SN, Khan S, Misba L, et al. Synergistic fungicidal activity with low doses of eugenol and amphotericin B against Candida albicans[J]. Biochem Biophys Res Commun, 2019, 518(3):459-464.
34 Manoharan RK, Lee JH, Kim YG, et al. Inhibitory effects of the essential oils α-longipinene and linalool on biofilm formation and hyphal growth of Candida albicans[J]. Biofouling, 2017, 33(2):143-155.
35 Singh S, Uppuluri P, Mamouei Z, et al. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection[J]. PLoS Pathog, 2019, 15(8):e1007460.
36 Kamikawa Y, Fujisaki J, Nagayama T, et al. Use of Candida-specific chicken egg yolk antibodies to inhibit the adhering of Candida to denture base materials: prevention of denture stomatitis[J]. Gerodontology, 2016, 33(3):342-347.
37 Wan L, Zhang Y, Lai Y, et al. Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV trial[J]. J Clin Oncol, 2015, 33(34):3999-4006.
38 Fites JS, Gui M, Kernien JF, et al. An unappreciated role for neutrophil-DC hybrids in immunity to invasive fungal infections[J]. PLoS Pathog, 2018, 14(5):e1007073.
39 Freire F, Ferraresi C, Jorge AO, et al. Photodynamic therapy of oral Candida infection in a mouse model[J]. J Photochem Photobiol B, 2016, 159:161-168.
40 Seyedmousavi S, Hashemi SJ, Rezaie S, et al. Effects of low-level laser irradiation on the pathogenicity of Candida albicans: in vitro and in vivo study[J]. Photomed Laser Surg, 2014, 32(6): 322-329.
Options
Outlines

/

〈 〉